Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Publication|Videos|May 13, 2024
Talking Strategic Development with Simtra at DCAT
Author(s)Simtra BioPharma Solutions
Ray Guidotti, Chief Operating Officer at Simtra BioPharma Solutions, talks about the company's strategic development and how it supports customers with a focus on excellence.
Simtra BioPharma Solutions is a premier contract development and manufacturing organization (CDMO) with more than 65 years of sterile injectable (SI) experience and a dedicated focus on providing a range of services from clinical development to commercial fill/finish. Learn more about:
- Simtra’s new building in Halle that features a high-speed syringe line and vial line equipped with four lyophilizers and is expected to be GMP ready in 2024.
- The new clinical line in Bloomington that will be ready to take on projects in the summer of 2025.
- Construction of the new state-of-the-art building in Bloomington that will begin in the summer of 2024.
Related to this article
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.